Skip to main content

09-16-2017 | Sexual dysfunction | Practical approach | Article

A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes

Journal: Diabetes Therapy

Authors: Charmaine Rochester-Eyeguokan, Lisa Meade

Publisher: Springer Healthcare



Female sexual dysfunction (FSD) is highly prevalent in women with diabetes mellitus (DM), yet it remains unaddressed, undiagnosed, and untreated. Hypoactive sexual desire disorder (HSDD) is the most common complaint among women with FSD, but there is a paucity of research into its multifactorial etiology. Flibanserin is the only therapy approved by the US Food and Drug Administration for treating acquired, generalized HSDD in premenopausal women. Women with DM diagnosed with HSDD may require a multidisciplinary approach for optimal management.
Enzlin P, Rosen R, Wiegel M, et al. Sexual dysfunction in women with type 1 diabetes. Diabetes Care. 2009;32:780–5. CrossRefPubMedPubMedCentral
Doruk H, Akbay E, Cayan S, et al. Effect of diabetes mellitus on female sexual function and risk factors. Arch Androl. 2005;51:1–6. CrossRefPubMed
Enzlin P, Mathieu C, Van den Bruel A, et al. Prevalence and predictors of sexual dysfunction in patients with type 1 diabetes. Diabetes Care. 2003;26:409–14. CrossRefPubMed
Mimoun S, Wylie K. Female sexual dysfunctions: definitions and classification. Mauritas. 2009;63:116–8.
Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet. 2010;110:7–11. CrossRefPubMed
Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114–28. CrossRefPubMed
Kingsberg SA, Iglesia CB, Kellogg S, et al. Handbook on female sexual health and wellness. Association of Reproductive Health Professionals. http://​www.​arhp.​org/​Publications-and-Resources/​Clinical-Practice-Tools/​Handbook-On-Female-Sexual-Health-And-Wellness ARHP 2011:1–24. Accessed 31 Aug 2017.
Miocic J, Car N, Metelko Z. Sexual dysfunction in women with diabetes mellitus. Diabetologia Croatica. 2008;37:35–42.
Palacios S, Casta R, Grazziotin A. Epidemiology of female sexual dysfunction. Mauritas. 2009;63:119–23.
Buster JE. Managing female sexual dysfunction. Fertil Steril. 2013;100:905–15. CrossRefPubMed
Clayton AH, Goldfischer ER, Goldstein I, et al. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009;6:730–8. CrossRefPubMed
US FDA. FDA approves first treatment for sexual desire. https://​www.​fda.​gov/​newsevents/​newsroom/​pressannouncemen​ts/​ucm458734.​htm. Accessed 19 June 2017.
Katz M, Derogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807–15. CrossRefPubMed
Goldfischer ER, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder results from a randomized withdrawal trial. J Sex Med. 2011;8:3160–72. CrossRefPubMed
Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women, a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–62. CrossRefPubMed
Woodis CB, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy. 2012;32(1):38–53. CrossRefPubMed
Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3489–510. CrossRefPubMed
Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communication with patients on sexual health. Pharmacotherapy. 2013;33(4):411–21. CrossRefPubMed
Safarinejad MR, Hosseini SY, Asgari MA, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010;106:832–9. CrossRefPubMed